Email this article The status of epidermal growth factor receptor and topoisomerase IIα genes in triple-negative breast cancer cells
- Authors: Karseladze D.A.1, Poddubnaya I.V.2, Karseladze A.I.3
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
- Department of Oncology, Russian Medical Academy of Postgraduate Education, Russian Agency for Health Care
- Department for Pathological Anatomy of Human Tumors, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: No 4 (2010)
- Pages: 33-39
- Section: MAMMOLOGY. NEW TECHNOLOGIES
- Published: 29.11.2010
- URL: https://ojrs.abvpress.ru/ojrs/article/view/266
- DOI: https://doi.org/10.17650/1994-4098-2010-0-4-33-39
- ID: 266
Cite item
Full Text
Abstract
The paper gives the results of studying the genes of epidermal growth factor receptor (EGFR) and topoisomerase IIα (TOP IIα) in patients with triple-negative breast cancer (BC). It is suggested that the lack of EGFR gene amplification might serve as a factor of good prognosis. TOP IIα gene amplification usually occurs in the tumors responsive to chemotherapy including anthracycline drugs. The altered status of the above genes should be interpreted in the context of aneusomy of chromosomes 7 and 17, on which they are located. No association was found between the pattern of EGFR and TOP IIα gene abnormalities and the basaloid phenotype of BC.
About the authors
D. A. Karseladze
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Author for correspondence.
Email: dima_karseladze@mail.ru
Russian Federation
I. V. Poddubnaya
Department of Oncology, Russian Medical Academy of Postgraduate Education, Russian Agency for Health CareRussian Federation
A. I. Karseladze
Department for Pathological Anatomy of Human Tumors, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowRussian Federation
References
Supplementary files
